


**Product Name** : Enozertinib  
**Cat. No.** : PC-24132  
**CAS No.** : 2489185-38-6  
**Molecular Formula** : C<sub>35</sub>H<sub>42</sub>F<sub>2</sub>N<sub>8</sub>O<sub>3</sub>  
**Molecular Weight** : 660.77  
**Target** : EGFR  
**Solubility** : 10 mM in DMSO



CAS: 2489185-38-6

## Biological Activity

Enozertinib (ORIC-114) is a potent, brain penetrant, orally bioavailable, irreversible inhibitor of exon 20 insertions in **EGFR** and HER2.

ORIC-114 is highly selective for the EGFR family of receptors, with excellent kinome selectivity compared to other reported exon 20 inhibitors, reducing the risk of off-target kinase liabilities.

ORIC-114 administration (3 mg/kg, once daily oral) induced robust tumor regressions with greater than 100% tumor growth inhibition in the absence of significant body weight loss in an EGFR exon 20 insertion H773\_V774insNPH NSCLC PDX model.

## References

- Patent WO2020190119 A1.
- Jason E. Long, et al. *Cancer Res* (2022) 82 (12\_Supplement): 3335.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com